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Abstract
Parasite-specific antibodies protect against blood-stage Plasmodium infection. However,
in malaria-endemic regions, it takes many months for naturally-exposed individuals to
develop robust humoral immunity. Explanations for this have focused on antigenic varia-
tion by Plasmodium, but have considered less whether host production of parasite-spe-
cific antibody is sub-optimal. In particular, it is unclear whether host immune factors might
limit antibody responses. Here, we explored the effect of Type I Interferon signalling via
IFNAR1 on CD4+ T-cell and B-cell responses in two non-lethal murine models of malaria,
P. chabaudi chabaudi AS (PcAS) and P. yoelii 17XNL (Py17XNL) infection. Firstly, we
demonstrated that CD4+ T-cells and ICOS-signalling were crucial for generating germinal
centre (GC) B-cells, plasmablasts and parasite-specific antibodies, and likewise that T
follicular helper (Tfh) cell responses relied on B cells. Next, we found that IFNAR1-signal-
ling impeded the resolution of non-lethal blood-stage infection, which was associated with
impaired production of parasite-specific IgM and several IgG sub-classes. Consistent
with this, GC B-cell formation, Ig-class switching, plasmablast and Tfh differentiation
were all impaired by IFNAR1-signalling. IFNAR1-signalling proceeded via conventional
dendritic cells, and acted early by limiting activation, proliferation and ICOS expression by
CD4+ T-cells, by restricting the localization of activated CD4+ T-cells adjacent to and
within B-cell areas of the spleen, and by simultaneously suppressing Th1 and Tfh
responses. Finally, IFNAR1-deficiency accelerated humoral immune responses and par-
asite control by boosting ICOS-signalling. Thus, we provide evidence of a host innate
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cytokine response that impedes the onset of humoral immunity during experimental
malaria.
Author Summary
Plasmodium parasites cause malaria by invading, replicating within, and rupturing out of
red blood cells. Natural immunity to malaria, which depends on generating Plasmodium-
specific antibodies, often takes years to develop. Explanations for this focus on antigenic
variation by the parasite, but consider less whether antibody responses themselves may be
sub-optimal. Surprisingly little is known about how Plasmodium-specific antibody
responses are generated in the host, and whether these can be enhanced. Using mouse
models, we found that cytokine-signallingvia the receptor IFNAR1 delayed the produc-
tion of Plasmodium-specific antibody responses. IFNAR1-signalling hindered the resolu-
tion of infection, and acted early via conventional dendritic cells to restrict CD4+ T-cell
activation and their interactions with B-cells. Thus, we reveal that an innate cytokine
response, which occurs during blood-stagePlasmodium infection in humans, obstructs
the onset of antibody–mediated immunity during experimentalmalaria.
Introduction
Although robust immunity to malaria is difficult to generate in humans through natural infec-
tion or vaccination [1,2], it is nonetheless clear that Plasmodium-specific antibodies offer the
best known form of immunological protection against blood-stage parasites [3,4,5,6,7,8], and
may also control liver-infective sporozoites [9,10]. Considering that a highly effectivemalaria
vaccine remains elusive, it is important to understand how the onset of humoral immunity to
blood-stagePlasmodium parasites is controlled, and whether this process can be boosted, to
accelerate or otherwise enhance antibody-mediated immunity to malaria.
Mouse models of resolving, non-lethal blood-stagePlasmodium infection are useful for
studying humoral immunity to malaria, since mice fail to control parasitemias and display
increased disease severity in the absence of parasite-specific antibodies [4,11,12,13,14]. How-
ever, our understanding of how humoral immune responses develop in these models is cur-
rently modest. CD4+ T follicular helper (Tfh) cells and their associated cytokines, such as IL-
21, and germinal centre (GC) B-cells are critical mediators of humoral immune responses in
many systems [15,16], and appear to be similarly important during experimentalmalaria. For
instance, an anti-parasitic role for T-cell-derived IL-21 was recently describedduring non-
lethal Plasmodium chabaudi chabaudi AS (PcAS) infection [6]. Other recent studies using non-
lethal Plasmodium yoelii 17XNL (Py17XNL) infection focused on co-stimulatorymarkers on
CD4+ T-cells, and demonstrated that Programmed cell Death 1 (PD-1) and LAG-3 blockade,
or stimulation via OX40 boosted Tfh and GC B-cell responses, with positive effects on parasite
control [4,17]. With the exception of these reports, in vivo studies of Tfh cells and GC B-cells
during experimentalmalaria remain sparse. Moreover, while these recent reports focused on
molecules expressed by CD4+ T-cells themselves, less effort has been directed towards deter-
mining whether T-cell extrinsic factors, such as innate or inflammatory cytokines, can control
humoral immunity.
It is becoming increasingly clear that inducible T-cell co-stimulatory (ICOS) receptor on
CD4+ T-cells is vital for Tfh cell-dependent humoral immunity across numerous model
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systems [18,19]. ICOS has been implicated in Tfh differentiation via the stabilization of the
transcription factor B-cell lymphoma-6 (Bcl-6) [18,20,21]. Importantly, ICOS supports inter-
actions of emerging Tfh cells with ICOS ligand (ICOSL)-expressing bystander B-cells at the
periphery of B-cell follicles, a pivotal process for GC B-cell formation and maintenance
[22,23]. Moreover, ICOS facilitates the expression of CXCR5, a chemokine receptor essential
for Tfh migration into B-cell zones [18,24]. Despite fundamental roles for ICOS on CD4+ T-
cells in generating and optimizing B-cell responses and antibody production, its role during
blood-stagePlasmodium infectionwas largely unexplored until recently [25], whenWikenhei-
ser et al. describedweaker Tfh and B-cell differentiation in ICOS-deficientmice after the first
week of PcAS infection. Furthermore, although T-cell-intrinsic mechanisms have been defined
for regulating CD4+ T-cell ICOS levels, for example via Roquin1 and 2 [26,27] and micro-
RNA146a [28], whether or not T-cell extrinsicmechanisms can also modulate ICOS is unclear
at present.
Type I interferon (IFN-I) signalling can amplify adaptive immune responses [29,30,31], and
drive humoral immunity in vivo, particularly in the context of immunization [32,33], viral
infection [34,35] and autoimmunity [29,36]. Furthermore, IFN-I-signallingwas reported to
induce Bcl6, CXCR5 and PD1 expression in naïve CD4+ T cells following TCR stimulation in
vitro [37]. IFN-I-related immune responses have also been observed in PBMC frommalaria
patients [38,39,40]. Although their functional relevance in humans remains to be established,
we recently showed in ex vivo cultures of PBMC from P. falciparum-infected humans, that sig-
nalling via IFNAR2 was immunoregulatory [41]. In addition, we showed in experimentalmice
that IFNAR1-signalling, acting via conventional dendritic cells (cDCs) [42], and employing the
canonical IFN-I transcription factor, IRF7 but not IRF3 [43], suppressed Th1 responses and
parasite control during experimental severe malaria caused by P. berghei ANKA (PbANKA).
Recent data has suggested that increased Th1 responses might suppress Tfh cells via IFNγ-sig-
nalling in experimentalmalaria [17], and viral infection [44]. Therefore, the current literature
supports a model in which IFNAR1/2-signalling suppresses Th1 responses yet promotes Tfh-
dependent humoral immunity during blood-stagePlasmodium infection. The aim of this paper
was to determine the effect of IFNAR1-signalling on humoral immune responses during exper-
imental malaria.
In this report, we investigated roles for CD4+ T cells, ICOS- and IFNAR1-signalling path-
ways in the development of humoral immune responses during blood-stagePlasmodium infec-
tion.We confirmed crucial roles for CD4+ T-cells and ICOS-signalling in controlling B-cell
responses and anti-parasitic immunity. We showed that IFNAR1-signalling obstructedparasite
control and antibody production, which was associated with regulation of numerous aspects of
the humoral immune response including GC B-cell and plasmablast generation. In particular,
IFNAR1-signalling acted early to limit proliferation and localization of activated CD4+ T-cells
adjacent to and within B-cell follicles in the spleen. Finally, IFNAR1-deficiency boosted
humoral immune responses and improved parasite control in an ICOS-dependentmanner.
Thus, we describe here the restrictive effect of an innate cytokine-signallingpathway on anti-
body-mediated immunity during experimental blood-stagemalaria.
Results
GC B-cell and plasmablast differentiation requires CD4+ T-cells and
ICOS-signalling during blood-stage Plasmodium infection
CD4+ T-cells are critical for control and resolution of blood-stagePlasmodium infection
[4,11,45], a phenomenon we first confirmed in Py17XNL-infectedWTmice depleted of CD4+
cells (Fig 1A & 1B). Despite this, to our knowledge there remained no direct evidence that
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Fig 1. Splenic Germinal Centre B-cell and plasmablast responses are strongly dependent on CD4+
cells during blood-stage Plasmodium infection. (A) Parasitemia and (B) survival of WT mice (n = 6)
treated with CD4-depleting monoclonal antibody (αCD4) or control IgG 1 day prior to infection with Py17XNL.
(C) Flow cytometric gating strategy employed to analyze splenic B-cell responses throughout the
manuscript. (D-F) WT mice (n = 5) were administered αCD4 or control-IgG prior to Py17XNL infection.
Presented are representative FACS plots (gated on B220+ CD19+ live singlets), proportions and absolute
numbers in the spleen of (D) plasmablasts (IgDlo CD138hi), (E) GC B-cells (GL-7+ Fas+), and (F) Ig-switched
B-cells (IgDlo IgMlo cells) from naïve and infected, control IgG and αCD4-treated WT mice, 10 days p.i.
Statistics: Mann-Whitney U test, **P<0.01, except (B) in which Log-rank test applied (** p = 0.0012).
Experiment in A&B done once, C-F representative of two independent experiments.
doi:10.1371/journal.ppat.1005999.g001
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CD4+ T cells promoted B-cell responses during experimentalmalaria. To examine this, wild-
type (WT) mice depleted of CD4+ cells or given control IgG, were infected with Py17XNL and
examined for resulting splenic GC B-cell and plasmablast responses (Fig 1C). By day 10 post-
infection (p.i), a timepoint just before the CD4-depletedmice began to succumb to infection,
plasmablast differentiation was 80% lower in CD4-depletedmice compared to infected con-
trols (Fig 1D), and GC B-cell formation (Fig 1E) was almost abrogated (95% reduction com-
pared to controls), with a similar, substantial impairment in Ig-class switching (Fig 1F).
Together, these data formally demonstrated that GC B-cell and plasmablast generation was
highly dependent upon CD4+ T-cells.
While previous studies in mice and humans demonstrated that ICOS expressed on CD4+
T- cells was critical for effective humoral responses [18,19,23,46,47], until recently, no such
studies had been performed during Plasmodium infection [25]. Therefore, we first examined
ICOS expression by CD4+ T-cells during Py17XNL infection (Fig 2A), revealing significant
up-regulation by 5–7 days p.i. (Fig 2B), which progressively increased over the following 7–9
days. To examine a possible functional role for ICOS in the development of humoral immu-
nity, WTmice were treated with α-ICOSL-blocking antibody (α-ICOSL) during Py17XNL-
infection. Consistent with other experimentalmodels [18,19,48], ICOSL-blockade impaired
GC B-cell formation (Fig 2C), Ig-class switching (Fig 2D), Tfh differentiation (Fig 2E), and
early production by day 16 p.i. of parasite-specific total IgG and IgG2b, but not IgM or IgG3
in the serum (Fig 2F). Day 16 p.i. was an important timepoint during Py17XNL infection
because it marked the point at which the rate of increase in parasitemia began to slow in WT
mice, thus indicating the beginning of the resolution phase of infection. Finally, ICOSL-
blockade over the first three weeks of infection exacerbated parasitemias and delayed resolu-
tion of infection (Fig 2G). Taken together, these data indicated that ICOS-signalling promoted
CD4+ T-cell dependent humoral immune responses and parasite control during Py17XNL-
infection.
IFNAR1-signalling impairs B-cell and antibody responses during blood-
stage Plasmodium infection
We next examined the impact of IFNAR1-signalling on parasite control and humoral immune
responses during Py17XNL-infection. Ifnar1-/- mice displayed similar initial parasitemias com-
pared to infectedWT controls for the first two weeks of infection, but thereafter exhibited
faster control of blood-stage parasites thanWT controls (Fig 3A). Similar effects were also
observedduring PcAS-infection (S1A Fig). Next, we noted increased parasite-specific IgM and
total IgG levels in the sera of Py17XNL-infected Ifnar1-/-mice compared toWT controls at day
16 p.i. (Fig 3B & 3C). More specifically, levels of parasite-specific IgG1, IgG2b, IgG2c and IgG3
were all higher in Ifnar1-/-mice compared toWT controls (Fig 3B & 3C). Next, we noted that
GC B-cell (Fig 3D) and Ig-switched B-cell generation (Fig 3E) was limited by IFNAR1-signal-
ling at day 16 p.i. In addition, IFNAR1-signalling impaired plasmablast formation at day 6 p.i.
(Fig 3F). We also observed similar regulation of plasmablasts and emerging GC B-cells during
PcAS-infection (S1B & S1C Fig). Finally, we explored the longer-term effect of IFNAR1-signal-
ling on parasite-specific antibody production. At day 25 p.i. with Py17XNL, Ifnar1-/- mice
maintained higher serum IgG levels, including IgG2b and IgG3, but not IgM, compared toWT
controls (Fig 3G). By day 40 p.i., total IgG, IgG2b and IgG3 concentrations had risen further to
similar levels inWT and Ifnar1-/-mice, while IgM levels had dropped, again with no differences
between groups (Fig 3G). Taken together, our data indicated that IFNAR1-signalling delayed
parasite control, B-cell responses and the onset of antibody production during blood-stage
Plasmodium infection.
IFNAR1 Obstructs Humoral Immunity to Malaria
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Fig 2. ICOS-signalling promotes humoral immune responses during blood-stage infection. (A) Flow cytometric gating
strategy employed to analyze splenic CD4+ T-cell responses throughout the manuscript. (B) Representative FACS plots and
time-course analysis of cell-surface ICOS expression on splenic CD4+ T-cells from WT mice (n = 3/time point) during
Py17XNL infection. (C-F) WT mice (n = 6/group) were treated with anti-ICOSL blocking monoclonal antibody (α-ICOSL) or its
isotype control (rat-IgG2a) prior to and during infection with Py17XNL. (C) Representative FACS plots (gated on B220+ CD19+
live singlets), proportions and numbers of splenic GC B-cells (GL-7+ Fas+), (D) numbers of splenic Ig-class switched (IgDlo
IgMlo) B-cells, and (E) representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions and numbers of splenic
Tfh cells (PD1+ CXCR5+), in naïve mice and infected, α-ICOSL and control IgG-treated mice, 16 days p.i. (F) Py17XNL-
specific IgM, total IgG, IgG2b and IgG3 levels in serum of naïve and infected, α-ICOSL and control IgG-treated mice, 16 days
p.i. (G) Parasitemias in WT mice (n = 6/group) infected with Py17XNL, and treated every three days with α-ICOSL or control
IgG until day 21 p.i. (depicted by arrows, with estimated period of cover highlighted with shaded grey box—an α-ICOSL-
treated mouse succumbed to infection on each of days 15, 17 and 30 p.i., and one control-IgG treated mouse succumbed on
day 20 p.i. Data representative of two independent experiments in (B-E), and two pooled independent experiments in (F), with
experiment in (G) being conducted once. Statistics: Mann-Whitney U test, *P<0.05; **P<0.01.
doi:10.1371/journal.ppat.1005999.g002
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Fig 3. IFNAR1-signalling obstructs B-cell and parasite-specific antibody responses during blood-stage infection. (A)
Time-course analysis of parasitemia in WT and Ifnar1-/-mice (n = 5/group) infected with Py17XNL. (B) ELISA quantitation of
Py17XNL-specific IgM, total IgG, IgG1, IgG2b, IgG3 in serum diluted from 1 in 400 in two-fold sequential dilutions to 1 in 3200,
and (C) IgG2c at 1 in 400 in the sera of naïve and infected WT and Ifnar1-/- mice, 16 days p.i. (D&E) Representative FACS plots
(gated on B220+ CD19+ live singlets), proportions and absolute numbers of (D) splenic GC B-cells (GL7+ Fas+) and (E) Ig-class-
switched B-cells (IgDlo IgMlo) in naïve and infected WT and Ifnar1-/- mice, 16 days p.i. (F) Representative FACS plots (gated on
B220+ CD19+ live singlets), proportions and absolute numbers of splenic plasmablasts (IgDloCD138hi) in naïve and infected WT
and Ifnar1-/- mice (n = 6), 6 days p.i. (G) Time course analysis of IgM, total IgG, IgG2b and IgG3 levels in naïve and infected WT
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IFNAR1-signalling limits Tfh differentiation and CD4+ T cell localization
adjacent to B-cell areas of the spleen
Given that GC B-cell and plasmablast formation was dependent on CD4+ T cells (Fig 1D–1F),
and likewise that Tfh differentiation depended on the presence of B-cells (S2 Fig), we next
examined the impact of IFNAR1-signalling on splenic CD4+ T-cell responses (Fig 4). Com-
pared to infectedWT controls, Ifnar1-/-mice displayed increased Tfh proportions and num-
bers during Py17XNL infection (Fig 4A), and increased proportions during PcAS infection (Fig
4B). We chose to assess emerging Tfh cells around day 6–8 p.i. during PcAS infection, since
our previous work had suggested that strong CD4+ T helper cell responses were detectable
around this time [43,49]. Enhanced Tfh differentiation was associated in both models with a
substantial increase by 6 days p.i., in ICOS expression by splenic CD4+ T-cells (Fig 5A & 5B).
ICOS expression by CD4+ T cells facilitates interaction with ICOSL-expressing B-cells at the
periphery of B-cell zones, and sustains Tfh cells within B-cell follicles [19,22,23]. Therefore, we
examined the impact of IFNAR1-signalling on CD4+ T-cell localizationwithin the spleen (Fig
5C). At day 5 p.i. we observedhigher densities of ICOS+ T-cells at the T/B border in Ifnar1-/-
mice compared to WT controls (Fig 5C), with a similar althoughmore modest effect within B-
cell follicles themselves (Fig 5C). Therefore, our data suggested that IFNAR1-signalling limited
Tfh cell differentiation and the localization of activated CD4+ T-cells adjacent to and within B-
cell follicles.
To rule out possible developmental or immune homeostatic defects in Ifnar1-/-mice
accounting for phenomena described above, we next treated PcAS-infectedWTmice with an
IFNAR1-blocking antibody [42,43]. IFNAR1-blockade enhanced ICOS expression on CD4+
T-cells (Fig 6A), boosted Tfh cell responses but not Bcl-6 expression (Fig 6B), and increased
early plasmablast and GC B-cell formation (Fig 6C & 6D). Together, these data supported the
hypothesis that IFNAR1-signalling regulated ICOS expression by CD4+ T-cells, limited Tfh
differentiation, and restricted splenic B-cell responses.
IFNAR1-signalling limits both Th1 and Tfh differentiation
Elevated IFNγ responses during blood-stagemalaria have been associated with impaired
humoral immune responses [17,50,51]. Since IFNAR1-signalling had suppressed IFNγ produc-
tion by Th1 cells in our previous reports using PcAS and PbANKA infection [42,43], we next
determined the concurrent effect of IFNAR1-signalling on Th1 and Tfh differentiation. On day
6 p.i. with PcAS, as expected, Ifnar1-/- mice exhibited increased Th1 differentiation compared
toWT controls [43] (Fig 7A). Importantly, emerging Tfh responses at day 6 p.i. were also
higher in Ifnar1-/- mice compared to WT controls (Fig 7B). This indicated that IFNAR1-signal-
ling had simultaneously limited both Th1 and Tfh cell formation, rather than skewed CD4+ T
cell responses to either helper subset. Moreover, IFNAR1-mediated regulation of ICOS expres-
sion in CD4+ T cells was observed in both the Th1 and emerging Tfh compartments during
PcAS infection (Fig 7C); and IFNAR1-signalling also reduced ICOS+ Tfh cell numbers during
Py17XNL infection (Fig 7D).
Next, given the simultaneous effect of IFNAR1-signalling on Th1 and Tfh differentiation,
we examined whether IFNAR1-signalling exerted a generalized effect on CD4+ T-cells. At day
6 p.i. during PcAS infection, the proportion of CD4+ T-cells that were proliferating, as assessed
and Ifnar1-/- mice (n = 6). Statistics: Mann-Whitney U test (A & C-G), Two way ANOVA and Tukey’s test for multiple comparisons
in (B), *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. Data representative of three independent experiments for (A), (D) and
(E), two for (B) and (F) and one for (C) and (G).
doi:10.1371/journal.ppat.1005999.g003
IFNAR1 Obstructs Humoral Immunity to Malaria
PLOS Pathogens | DOI:10.1371/journal.ppat.1005999 November 3, 2016 8 / 26
by Ki-67-staining (Fig 7E), was modestly higher in Ifnar1-/- mice compared to WT controls.
Similarly, in α-IFNAR1-treated Py17XNL-infectedmice at day 6 p.i., CD4+ T-cells were more
proliferative compared to isotype-treated controls (Fig 7F). We also examined the effect of
IFNAR1-signalling on CD4+ T-cell activation using the markers CD11a and CD49d [4,41]. At
day 8 p.i. with PcAS, the proportion of CD4+ T-cells co-expressing CD11a and CD49d was
modestly higher in Ifnar1-/- mice compared to WT controls, although absolute numbers in the
spleen were not different (S3A Fig). We also studied Py17XNL-infectedmice at day 6 p.i. after
treatment with α-Ifnar1. We noted again that CD4+ T-cells were more activated in α-Ifnar1-
treated mice compared to isotype-treated controls (S3B Fig). Taken together, our data sug-
gested that IFNAR1-signalling limited early CD4+ T-cell activation and proliferation.
Finally, we observedno substantial differences in the cellularity of the spleen, or bulk CD4+
T cell or B-cell numbers, inWT versus Ifnar1-/-mice during PcAS infection (Fig 7G),
Py17XNL infection (Fig 7H), or in un-infectedmice (S3C Fig). These data support the idea
that any increases in Th1 or Tfh cells observed in our studies were not due to generalized
increases in spleen cellularity, but instead were associated with specific regulation of CD4+ T
cell activation and proliferation. Taken together, our data revealed that IFNAR1-signalling
simultaneously regulated Th1 and Tfh cell formation, which was associated with restricted
CD4+ T-cell activation, proliferation and ICOS expression.
Fig 4. IFNAR1-signalling limits splenic Tfh cell responses. (A) WT and Ifnar1-/- mice (n = 5/group) were
infected with Py17XNL, and splenic Tfh (PD1+ CXCR5+) cell proportions and absolute numbers were
assessed at day 16 p.i. Representative FACS plots gated on CD4+ TCRβ+ live singlets. Data representative
of three independent experiments; Mann-Whitney U test *P<0.05; **P<0.01. (B) WT and Ifnar1-/- mice
(n = 5-6/group) were infected with PcAS, and splenic Tfh (PD1+ CXCR5+ or Bcl-6+ CXCR5+) cell proportions
and absolute numbers were assessed at day 8 p. i. Representative FACS plots gated on CD4+ TCRβ+ live
singlets. Data representative of three independent experiments; Mann-Whitney U test *P<0.05; **P<0.01.
doi:10.1371/journal.ppat.1005999.g004
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IFNAR1-signalling via cDCs limits Tfh cell and GC B-cell responses
We next determined cell types in which IFNAR1-signalling had occurred, and focused on cDCs
given our previous work using lethal PbANKA infection [42]. We generated mixed bonemar-
row chimeric mice as before [42], which harboured equal proportions of WT and Ifnar1-/-
splenic cDCs (Fig 8A). These mice were infectedwith Py17XNL, and expression of co-stimula-
torymolecules was assessed at the peak of the cDC response (at 2 days p.i.) on splenic WT and
Ifnar1-/- cDC subsets (Fig 8B). Up-regulation of CD86 in particular, which we previously found
was dependent on IFNAR1-signalling in cDC [42], was again substantially impaired in Ifnar1-/-
CD8+ and CD8- cDC subsets compared toWT cDCs (Fig 8C). A similar pattern of expression
was seen for PD-L1, while we observedminimal changes in ICOSL expression (Fig 8C). Inter-
estingly, we also observed cDC subset-specific effects, with PD-L2 restrained by IFNAR1-sig-
nalling in CD8- cDC subsets, and CD40 expression mediated by IFNAR1-signalling in CD8+
Fig 5. IFNAR1-signalling restricts CD4+ T-cell expression of ICOS and proximity to B cell areas of the spleen. (A)
Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions and absolute numbers of splenic ICOS+ CD4+
T-cells in naïve, and Py17XNL-infected WT and Ifnar1-/-mice (n = 6 per group) 6 days p.i. Experiment performed once.
Mann-Whitney U test **P<0.01. B) Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions and
absolute numbers of splenic ICOS+ CD4+ T-cells in naïve, and PcAS-infected WT and Ifnar1-/-mice (n = 6 per group) 6 days
p.i. Data representative of three independent experiments. Mann-Whitney U test **P<0.01. C) Representative confocal
microscopy images showing spleen sections from naïve (n = 2) and PcAS-infected WT and Ifnar1-/-mice (n = 5) on day 5 p.i.,
stained for ICOS (Green), CD3 (Blue), and B220 (Red). T-B borders are outlined by white dotted lines. Summary graphs
illustrate ICOS+ CD3+ cell densities for individual T/B borders and B cell follicles, with data pooled from four T-B borders or
follicles per mouse, (n = 2 for naïve and n = 5 for WT and Ifnar1-/- mice). Scale bar: 100μm. Mann-Whitney U test *P<0.05;
**P<0.01.
doi:10.1371/journal.ppat.1005999.g005
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cDCs (Fig 8C). Similar observationswere also made for CD86, CD40 and ICOSL during PcAS
infection (S4 Fig). Taken together, our data demonstrated that similar to lethal PbANKA infec-
tion [42], IFNAR1-signalling in splenic cDC subsets influenced their upregulation of co-stimu-
latory molecules during non-lethal blood-stagePlasmodium infection.
Fig 6. Antibody-mediated IFNAR1 blockade boosts humoral immune responses during blood-stage infection.
WT mice (n = 5/group) were treated with anti-IFNAR1 blocking antibody (α-Ifnar1) or control IgG prior to and during
infection with PcAS. (A) Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions and absolute
numbers of splenic ICOS+ CD4+ T cells in naïve and infected mice on days 6 and 7 p.i. (B) Representative FACS plots
(gated on CD4+ TCRβ+ live singlets), proportions and numbers of splenic Tfh cells (as PD1+CXCR5+ CD4+ T cells) in
naïve and infected and antibody-treated mice, 7 days p.i. Bcl-6 expression is also shown in histograms for Tfh
(PD1+CXCR5+; red gate) and non-Tfh cells (PD1-CXCR5-; blue gate), alongside Geometric Mean Bcl-6 expression by
these populations in individual mice. (C and D) Numbers of splenic (C) plasmablasts and (D) GC B cells in naïve, and
infected and treated mice, 7 days p.i. Data representative of 2 independent experiments. Mann-Whitney U test *P<0.05;
**P<0.01.
doi:10.1371/journal.ppat.1005999.g006
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Fig 7. IFNAR1-signalling simultaneously limits splenic Th1 and Tfh cell responses. (A & B) Representative
FACS plots (gated on CD4+ TCRβ+ live singlets), proportions and absolute numbers of splenic (A) Th1 (IFNγ+ Tbet+)
and (B) emerging Tfh (PD1+ CXCR5+) cells in WT and Ifnar1-/- mice (n = 6/group), 6 days p.i with PcAS. Data
representative of two independent experiments. (C) Numbers of splenic ICOS+ Th1 cells (Tbet+ IFNγ+ CD4+ T cells)
and Tfh cells (PD1+CXCR5+ CD4+ T cells) 6 days p.i. with PcAS. (D) Numbers of ICOS+ Tfh cells (PD1+CXCR5+ CD4+
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To study the possibility of IFNAR1-signalling in B-cells, we next examined early plasma-
blast responses in WT:Ifnar1-/-mixed bonemarrow chimeric mice during PcAS infection. At
day 7 p.i., there was no consistent increase in plasmablast formation by Ifnar1-/- cells compared
toWT counterparts (Fig 8D), suggesting that IFNAR1-signalling in B-cells played no major
role in regulating plasmablast differentiation.Moreover, in these same mice equal proportions
of WT and Ifnar1-/- CD4+ T cells upregulated ICOS and CXCR5 (Fig 8E). This suggested that
restriction of ICOS expression in emerging Tfh cells was not mediated by IFNAR1-signalling
directly to CD4+ T cells.
Finally, we explored in vivo the effect of IFNAR1-signalling in cDC on emerging humoral
responses in the spleen. CD11cCre+/- ifnar1f/f mice and CD11cCre-/- ifnar1f/f littermate con-
trols were infected with Py17XNL, and splenic Tfh and GC B-cell differentiation assessed 6
days p.i. (Fig 8F and 8G). We noted that IFNAR1-signalling in CD11chi cells limited both Tfh
(Fig 8F) and early GC B-cell (Fig 8G) differentiation. Taken together, our data strongly sug-
gested that regulation of humoral immune responses by IFNAR1-signalling was mediated
through cDCs, not B-cells or CD4+ T cells.
IFNAR1-deficiency boosts humoral immunity in an ICOS-dependent
manner
Finally, we sought to explore molecularmechanisms by which IFNAR1-deficiency accelerated
the onset of humoral immunity, and hypothesized a role for ICOS-signalling.To test this, we
adopted a recent approach in which α-ICOSL blocking antibody was used to reduce ICOS-sig-
nalling in mice exhibiting higher thanWT levels of ICOS [28]. We treated PcAS-infected
Ifnar1-/- andWTmice with a moderate dose of α-ICOSL blocking antibody (100μg) and at day
8 p.i. examined antibody production and parasitemia.We saw no effect on early parasite-spe-
cific IgM production or parasitemias inWTmice (Fig 9A & 9B), with some impairment of
emerging parasite-specific IgG responses (Fig 9A & 9B). In contrast, ICOS-signalling blockade
in Ifnar1-/- mice abrogated any improvements in parasite-specific IgM or IgG production (Fig
9A), and importantly, impaired parasite control compared to control-treated Ifnar1-/- mice
(Fig 9B). Consistent with these observations, we also noted that enhanced Tfh cell and GC B-
cell formation in Ifnar1-/- mice was strongly dependent on ICOS-signalling (Fig 9C & 9D).
Finally, ICOS blockade in Ifnar1-/-mice significantly reduced serum IFNγ levels compared to
control-treated Ifnar1-/- mice (S5 Fig), consistent with enhanced ICOS-signallingduring
IFNAR1-deficiency being supportive of Th1 differentiation. Taken together, our data support a
model in which IFNAR1-signalling limited humoral immune responses and parasite control
by regulating ICOS-signalling.
Discussion
Here, using two mouse models of non-lethal blood-stagemalaria, we have provided evidence
that the onset of protective humoral immunity to Plasmodium can be influenced by an innate
cytokine signalling pathway, in this case Type I Interferon-signalling via IFNAR1. Therefore,
T cells), 16 days p.i. with Py17XNL infection. (E) Proportions and absolute numbers of splenic CD4+ T-cells expressing
Ki-67 in naïve, WT and Ifnar1-/- mice 6 days p.i. with PcAS. (F) Proportions and absolute numbers of splenic CD4+ T-
cells expressing Ki-67 in naïve mice, and WT mice, 6 days p.i. with Py17XNL and treatment with α-IFNAR1 or Control
IgG. (G) Absolute numbers of splenocytes, CD4+ T-cells and B-cells, in WT naïve, infected WT and Ifnar1-/- mice 6
days (n = 17–18, pooled from three independent experiments (n = 5–6 per expt)) and 8 days (n = 29, pooled from five
experiments (n = 5–6 per expt)) p.i. with PcAS. (H) Absolute numbers of splenocytes, CD4+ T-cells and B-cells in WT
naïve, infected WT and Ifnar1-/- mice, 16 days p.i. with Py17XNL (n = 17–18, pooled from three experiments (n = 5–6
per expt)) Mann-Whitney U-test **P<0.01, *P<0.05.
doi:10.1371/journal.ppat.1005999.g007
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Fig 8. IFNAR1-signalling via cDCs limits Tfh and GC B-cell responses. (A) Schematic for the mixed bone marrow chimeric
approach: 50:50 mixed WT (Ifnar1+/+; CD45.1) and Ifnar1-/- (CD45.2) bone marrow was transferred into lethally-irradiated rag1-/- mice
(to avoid potential issues with residual radio-resistant T- and B-cells), and subsequently left for 8–12 weeks prior to infection studies. (B)
Gating strategy for splenic WT (CD45.1+) and Ifnar1-/- (CD45.2+) CD8+ (TCRβ- B220- CD11chi MHC-IIhi CD8α+) and CD8- (TCRβ- B220-
CD11chi MHC-IIhi Sirpα+ CD8-) conventional DCs. (C) Paired analysis between splenic WT and Ifnar1-/- cDC subsets in individual mice
for cell-surface expression of CD86, PD-L1, PD-L2, CD40 and ICOS-L, 2 days p.i. with Py17XNL. Data representative of two
independent experiments. Statistics: Wilcoxon test, *P<0.05. (D) Representative FACS plots and proportions for WT (CD45.1+) Ifnar1+/
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we have demonstrated for the first time that innate immune cytokines can limit the onset of
antibody production and B-cell responses to Plasmodium. Moreover, we found that release
from IFNAR1-mediated immune-regulation enhanced humoral immune responses and para-
site control in a manner dependent upon ICOS-signalling.
Although parasite-specific antibodies can control blood-stagePlasmodium parasite num-
bers in vivo, protective humoral immunity can take months or years to develop in humans.
Reasons for this have focused on parasite mechanisms such as antigenic variation, rather than
possible sub-optimal host immune responses. IFN-I responses have been well documented in
malaria patients [38,52,53]. Polymorphisms in the Ifnar1 gene have been associated with
reduced risk of severe malaria [38,52]. Although the location of polymorphisms did not indi-
cate the direction of their effect on IFNAR1-signalling, the implication was that changes in
IFNAR1-signalling could mediate improved parasite control. Indeed, our recent work using
C57BL/6J mice suggested that IFNAR1-signalling via IRF7 but not IRF3 limited parasite con-
trol during PcAS infection [42,43], although other recent work, using a different route of infec-
tion [54] or a different genetic background [55] suggestedmore modest roles for IFN-I-
signalling in mice. These different outcomes suggest possible context-dependent effects for
IFN-I-signallingduring PcAS infection.
It is likely that mousemodels of malaria will be informative for studies of cytokine-mediated
effects on humoral immunity, as recently epitomized in studies of T cell-derived IL-21 [6].
These reports and our new data complement studies of T-cell co-stimulatorymolecules, such
as PD-1 and LAG-3, and strengthen the idea that multiple molecular targets could be har-
nessed to boost humoral immunity to malaria [4,17]. Whether such strategies are more appli-
cable to natural exposure events or vaccination scenarios remains to be studied. In addition,
while we found no overt evidence of increased immune-pathology in Ifnar1-/- or α-Ifnar1
treated mice, it will be important to better test whethermanipulation of IFNAR1-signalling
triggers unwanted adverse events, as previously reported for IL-10- or IL-27-deficiency [56,57].
Much of our current understanding of cytokine-mediated control of humoral immunity
derives from studies of viral infection or experimental immunization in mice [33,58,59,60,61].
However, it remains difficult to infer from these studies how cytokine-signalling impacts upon
antibody responses during parasitic infection. In a recent report, Perez-Mazliah et al., demon-
strated a pivotal role for T cell-derived IL-21 in mediating GC B-cell responses and IgG class
switching but not for generating Tfh cells during blood-stagePlasmodium infection [6]. Our
demonstration that IFNAR1-signalling restricts the onset of humoral immunity to malaria is
the first description of cytokine-mediated suppression of Tfh, GC B-cell and plasmablast for-
mation during parasitic infection.More generally, while the majority of viral and experimental
immunization studies highlight a positive role for IFNAR1-signalling in driving humoral
immunity, our data emphasizes that depending on the experimental context, IFNAR1-signal-
ling can also limit humoral immune responses. Our previous studies using a lethal model of
malaria demonstrated that IFNAR1- signalling occurred via cDC,which resulted in potent sup-
pression of Th1-immunity, and was associated with effects on PDL1, PDL2 and IL-10 expres-
sion by cDC subsets [42]. However, the lethal model was not suitable for studying humoral
immunity, since mice becamemoribund within the first week of infection.Here, using non-
+ and Ifnar1-/- plasmablasts, 7 days p.i. with PcAS infection. Data representative of 2 independent experiments. Statistics: Wilcoxon test.
(E) Representative FACS plots and proportions for WT (CD45.1+) Ifnar1+/+ and Ifnar1-/- CD4+ T cells expressing ICOS and CXCR5, 7
days p.i. with PcAS infection. Experiment performed once. Statistics: Wilcoxon test, *P<0.05. (F) Representative FACS plots (gated on
CD4+ TCRβ+ live singlets), proportions and absolute numbers of splenic Tfh cells and (G) splenic GC B-cells (gated on B220+ CD19+
live singlets) in CD11cCre+/- ifnar1f/f and CD11cCre-/- ifnar1f/f littermates (n = 6) (WT naïve mice as staining controls), on day 6 p.i. with
Py17XNL; Statistics: Mann-Whitney U-test **P<0.01, *P<0.05. Data representative of 2 independent experiments.
doi:10.1371/journal.ppat.1005999.g008
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Fig 9. IFNAR1-deficiency boosts humoral immunity via enhanced ICOS-signalling. WT and Ifnar1-/-
mice (n = 6/group), infected with PcAS, and treated with αICOSL (100μg) or control IgG2a throughout
infection (days 0, 2, 4 and 6 p.i.), were assessed on day 8 p.i. for (A) parasite-specific IgM and IgG, as well as
(B) Parasitemia. (C&D) WT and Ifnar1-/- mice were infected with PcAS, and treated as in (A & B) with α-
ICOSL or control IgG2a: (C) Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions
and absolute numbers of splenic Tfh cells, and (D) proportions and absolute numbers of GC B-cells (gated
on B220+ CD19+ live singlets) on day 6 p.i. Statistics: One-way ANOVA, Tukey’s test for multiple
comparisons, *P<0.05; **P<0.01; ****P<0.0001. (A) & (B) representative of two independent experiments.
(C) & (D) representative of three independent experiments.
doi:10.1371/journal.ppat.1005999.g009
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lethal models, we similarly revealed that IFNAR1-signalling proceeding via cDCs, but not B- or
T-cells, regulated the generation of Tfh and GC B-cell responses. Given that cDCs are critical
for early Tfh differentiation and initiation of humoral immune responses [18,62,63], we pro-
pose that IFNAR1-signalling within splenic cDC regulates CD4+ T-cell proliferation, ICOS
expression, and Th1 and Tfh differentiation.
One question that remains to be answered is how the interaction between cDC and CD4+ T
cells is altered at a molecular level by IFNAR1-signalling. This work and our previous study
using PbANKA infection [42] both revealedmultiple changes in the co-stimulatory landscape
on the surface of cDC, including a substantial shift in the ratio of PDL1:PDL2 expression on
CD8- cDC.Given a recent report that PDL2-signalling can compete against the regulatory
effects of PDL1, and indeed, can protect against experimentalmalaria [64], we speculate that
IFNAR1-signalling in cDC regulates CD4+ T cell activation by favouring PDL1-signalling over
protective PDL2 signals.
It was recently reported during LCMV infection that IFN-I promoted Th1 responses, which
then suppressed Tfh and GC B-cell responses via IFNγ [44]. A more recent report using a
mouse model of malaria demonstrated that therapeutic release from PD-1 exhaustion, coupled
with stimulation via OX40 dramatically increased IFNγ production by Th1 cells, which desta-
bilized Bcl-6 in established Tfh cells and resulted in defective humoral immune responses [17].
Elsewhere, circulating ‘Th1-like’ Tfh cells were associated with impaired humoral responses in
children living in malaria endemic areas [50]. Most recently, Ryg-Cornejo et al., implicated a
combined effect of IFNγ and TNF in driving sub-optimal humoral responses during severe
malaria infections in mice [51]. Together, these data suggest that Th1 responses might interfere
with Tfh responses. However, in our studies, we found that deficiency in IFNAR1-signalling
triggered a concurrent increase in both Th1 and Tfh responses. This apparent discrepancy
between our work and recent studies could be explained by the differential kinetics of the ele-
vated Th1 responses in our respective studies. For instance, OX40- and PD1-targeted therapy
was initiated from the second week of infection, a period of time after which Th1/Tfh priming
would likely have occurred [17]. In our studies, elevated Th1 responses, as a result of IFNAR1-
deficiency, occurred relatively transiently within the first week of infection. Therefore, we spec-
ulate that elevated Th1 responses in IFNAR1-deficient mice did not destabilize Tfh responses
because they occurred early and were not prolonged.
Data from this and our previous studies [42,43,49] support a model in which abrogation of
IFNAR1-signalling has the dual effect of boostingTh1 responses and antibody-production.
These effects associated with improved control of Py17XNL, PcAS and PbANKA parasites; yet
crucially we have not yet demonstrated a causal link between IFNAR1-deficiency and
improved antibody-mediated parasite control. Nevertheless, we propose that depending upon
host genetic background and that of the infecting Plasmodium species, IFNAR1-signalling can
obstruct parasite control via a number of mechanisms including the regulation of Th1 cells
and/or antibody production.
Numerous studies across a range of experimental systems have established a pivotal role for
ICOS signalling in CD4+ T-cells in mediating T-cell dependent humoral immunity, via effects
on Tfh generation, maintenance and trafficking [18,19,23,65]. The importance of ICOS-signal-
ling is further highlighted by the existence of multiple layers of regulation within the T-cell for
limiting its expression, for example via Roquin 1, Roquin 2 and microRNA146a [26,27,28]. To
date, however, evidence of T-cell extrinsic mechanisms for controlling ICOS levels on CD4+ T-
cells has been limited. Our data reveals the existence of a cytokine signalling pathway, mediated
by IFNAR1 which serves to limit the level of ICOS on CD4+ T-cells. Currently, the mechanism
by which ICOS levels are modulated in our models by IFNAR1-signalling is unclear, but could
theoretically involve Roquin1, Roquin 2 or microRNA146a.
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Although we observed substantial early ICOS expression by activated CD4+ T-cells in our
models, we noted minimal change in ICOSL levels on cDC (Fig 8C). This might suggest that
boosting ICOS expression by CD4+ T-cells did not encourage further interaction with splenic
cDC. Instead, given that IFNAR1-deficiency increased the frequency of ICOS+ T-cells close to
and within B-cell follicles, which were themselves essential for supporting Tfh responses (S2
Fig), and since ICOSL-expressing B-cells are located at the periphery of B-cell follicles [22], we
propose that IFNAR1-signalling limits ICOS-mediated positioning of emerging Tfh cells adja-
cent to and within B-cell follicles during Plasmodium infection.However, further experiments
will be required to examine the effect of ICOS-signalling on CD4+ T-cell trafficking in the
spleen during experimentalmalaria.
In this study, we discovered that IFNAR1-deficiency accelerated early production of para-
site-specific IgM and IgG. If such mechanisms could be induced in humans, this might
improve control of parasite numbers and prevention of clinical malaria. However, the duration
of this effect would require scrutiny, since in our mouse models, antibody levels normalized
between Ifnar1-/- andWTmice by the seventh week of infection. Furthermore, whether accel-
eration in early antibody production would increase the rate of acquisition of immunity to clin-
ical malaria is also unclear, particularly given the phenomenon of antigenic variation.
However, we speculate that if subsequent infections were sufficiently similar from an antigenic
perspective to previously encountered parasites, short-term elevations in parasite-specific anti-
bodies could be beneficial. Finally, although we focused on studying the magnitude of parasite-
specific antibody responses within a given antibody sub-class, neither antibody affinity nor
avidity was examined. Therefore, further experimentation will be needed to determine whether
beneficial changes in antibody affinity and avidity can be brought about via cytokine
modulation.
In summary, we have demonstrated here that early cytokine-signallingduring infection
influences parasite-specific antibody production, and associated GC B-cell, plasmablast and
Tfh differentiation in two models of non-lethal blood-stagemalaria. Our work suggests that
antibody-mediated immunity to malaria might be improved by targeting cytokine-signalling
pathways, particularly in the context of natural infection.
Experimental Procedures
Ethics statement
All animal procedures were approved by the QIMR BerghoferMedical Research Institute Ani-
mal Ethics Committee, under approval numbers A02-633M and A1503-601M, in accordance
with the “Australian Code of Practice for the Care and Use of Animals for Scientific Purposes”
(Australian National Health and Medical Research Council).
Mice
Female C57BL/6J and congenic CD45.1+ C57BL/6J mice (6–12 weeks old) were purchased
from Australian Resource Centre (Canning Vale, Western Australia) and maintained under
conventional conditions. C57BL/6J Ifnar1-/- mice were maintained in-house at QIMR Bergho-
fer Medical Research Institute. Mixed bonemarrow (BM) chimeric mice were prepared as pre-
viously described [42]. Briefly, 2x106 fresh syngeneic BM cells from femurs of CD45.1+ wild
type and CD45.2+ Ifnar1-/- mice, mixed at a 50:50 ratio were intravenously (i.v.) transferred
into lethally irradiated [11Gy (137Cs source)] C57BL/6J Rag1-/- recipient mice. These mice
were then treated for 14 days with Baytril (Provet) in drinkingwater. Engraftment was assessed
after 8–12 weeks by flow cytometry. BM Chimericmice were infected 12 weeks after bonemar-
row transplantation.
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Parasites, infections and parasitemia
Non-lethal Plasmodium yoelii 17XNL (Py17XNL) and Plasmodium chaubadi chaubadi AS
(PcAS) parasites were used following one in vivo passage in wild type C57BL/6J mice. Using
parasitized red blood cells (pRBC) that were obtained from frozen/thawed stabilates, mice were
infected i.v. with either 104 pRBCs (Py17XNL) or 105 pRBCs (PcAS). Blood parasitemia was
measured in Diff-Quick (Lab Aids, Narrabeen, NSW, Australia) or giemsa-stained thin blood
smears obtained from tail bleeds. Alternatively, a modified protocol of a previously established
flow cytometricmethod was employed to measure parasitemia more rapidly [66]. Briefly, a sin-
gle drop of blood, from a tail bleed or cardiac puncture, was diluted and mixed in 250μl RPMI
containing 5U/ml heparin sulphate. Diluted bloodwas simultaneously stained with Syto84
(5μM; Life Technologies) to detect RNA/DNA, and Hoechst33342 (10μg/ml; Sigma) to detect
DNA, for 30 minutes, in the dark at room temperature. Staining was quenched with 10x vol-
ume of ice cold RPMI, and samples were immediately analysed by flow cytometry, using a BD
FACSCantoII analyser (BD Biosciences) and FlowJo software (Treestar, CA, USA). pRBCwere
readily detected as beingHoechst33342+ Syto84+, with white blood cells excluded on the basis
of size, granularity and much higher Hoechst33342/Syto84 staining compared to pRBC.
Preparation of crude parasite antigen
Crude antigen extract from Py17XNL or PcAS-infected RBCwas prepared using an adapted
version of a previously describedprotocol [67,68]. Briefly, mice were infected with Py17XNL
or PcAS as described above. When parasitemias reached 20–30%, bloodwas collected by car-
diac puncture into heparinized tubes. RBCs were washed once in RPMI at 1200rpm for seven
minutes at room temperature, and then lysed using ultrapure water followed by four washes in
ice-cold PBS at 16,000xg for 25 minutes at 4°C, as well as three cycles of freezing (two hours at
-80°C) and thawing (30 minutes at room temperature). Extracts were also processed from
RBCs of uninfectedC57BL/6J mice, for use as negative controls in ELISA. The concentration
of proteins in the purified extracts was determined by Bradford assay (Thermo Scientific).All
extracts were stored at -80°C until use.
Detection of parasite-specific serum antibodies by ELISA
Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4°C with 2.5μg of soluble
antigen/ml in bicarbonate coating buffer (pH9.6).Wells were washed three times (all washes in
0.005% Tween in PBS) and then blocked for 1hr at 37°C with 1% BSA in PBS. Wells were
washed three times, 100ul of sera diluted 1/400, 1/800, 1/1600 or 1/3200 was added and incu-
bated for 1hr at 37°C. Following six washes, wells were incubated in the dark with biotinylated
anti-IgM, total IgG, IgG1, IgG2b and IgG3 (Jackson ImmunoResearch) for 1hr at room tem-
perature. Unbound antibodies were washed off (six times) prior to incubating wells in the dark
with streptavidin HRP (BD pharmagen) for 30 minutes at room temperature. Wells were
washed six times prior to development (100μl, OPD; Sigma-Aldrich) for five minutes in the
dark before termination with an equal volume of 1M HCl. Absorbance was determined at
492nm using a Biotek synergyH4 ELISA plate reader (Biotek, USA). Data were analysed using
Gen5 software (version 2) and GraphPad Prism (version 6).
Flow Cytometry and Antibodies
Spleen mononuclear cells were prepared as previously described [69]. For studies of cDCs,
spleens were treated with deoxyribonuclease I (0.5mg/ml;Worthington Biochemical) and col-
lagenase type 4 (1mg/ml;Worthington Biochemical) for 25 minutes at room temperature, in
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order to ensure maximal recovery of splenic cDCs. Fluorescently conjugated monoclonal anti-
bodies, anti-mouse B220-Alexa Fluor 700 (RA3-6B2), B220-Pacific blue (RA3-6B2), CD19-
FiTC (6D5), CD138-BV605 (281–2), IgD-APCCy7 (11-26c.2a), IgM-PECy7 (RMM-1), TCRβ-
Alexa Fluor 700 (H57-597), TCRβ-APC/Cy7 (H57-597), CD4-BV605 (RM4-5), IFNγ-BV421
(XMG1.2), ICOS-PE (7E.17G9), Streptavidin-PE/Cy7, CD45.1-FiTC (A20), CD45.2-Alexa
Fluor 700 (104), CD11c-APC (N418), MHCII-Pacific blue (M5/114.15.2), CD8α-PE/Cy7 (53–
6.7), CD40-PE (1C10), CD80-PE (16-10A1), CD86-PE (GL1), ICOSL-PE (B7-RP1), PDL1-PE
(MIH5), PDL2-PE (TY25), CD49d-Biotin (R1-2), CD11a-FiTC (M17/4), Ki-67-PE (16A8) and
Zombie Aqua fixable viability dye were purchased from Biolegend (San Diego, CA). Anti-
mouse CD95/Fas-BV421 (Jo2), CXCR5-biotin (2G8), and Bcl6-PerCP/Cy5.5 (K112-91) were
purchased from BD Biosciences (Franklin Lakes, NJ). Anti-mouse T-bet-APC (eBio4B10), GL-
7-APC (GL-7) and PD1-APC/Cy7 (J43) were purchased from eBioscience. Cell surface and
intracellular IFNγ, T-bet and Bcl6 staining was performed as previously described [69,70].
In vivo cell depletion and blockade using monoclonal antibodies
Anti-CD4 depletingmonoclonal antibody (clone GK5.1) and its isotype control were adminis-
tered in 0.1mg doses, via intravenous (i.v.) injection in 200μl 0.9% NaCl (Baxter) one day
before infection. CD4+ T-cell depletion was confirmed in PBMC over the first four days of
infection, and absolute numbers subsequently remained>99% depleted in the spleen at day 10
p.i. compared to isotype-treated controls. For ICOSL blockade in Fig 2A–2F, α-ICOSL (clone
HK5.3, BioXCell) and its isotype control (IgG2a, clone 2A3, BioXCell) were administered in
0.2mg doses, via i.v. injection in 200μl 0.9% NaCl (Baxter) one day prior to infection, and then
every three days for up to 15 days p.i. (and for up to 21 days in Fig 2G). For ICOSL blockade
experiments in Fig 9 and S5 Fig, α-ICOSL (clone MIL5733) and its isotype control (IgG2a,
clone 1D10) were generated in-house and administered in 0.1mg doses, via i.v. injection in
200μl 0.9% NaCl (Baxter) one day prior to infection, and then every two days for up to 6 days
p.i. (In Fig 9, the 100μg dose was employed since preliminary experiments indicated that 200μg
reduced Tfh cell responses by ~65%, 100μg reduced Tfh responses by 50%, and 25μg had no
effect by day 8 p.i. with PcAS). For B-cell depletion, anti-CD20 (clone 5D2) or its isotype con-
trol antibody were produced and kindly provided by Genentech and administered in a single
0.5mg dose via i.p. injection in 200μl 0.9% NaCl (Baxter), five days prior to infection. For
Ifnar1 blockade, α-Ifnar1 blockingmonoclonal antibody (clone MAR1-5A3; Leinco Technolo-
gies Inc) and its isotype control mAb were administered in 0.1mg doses, via i.p. injection in
200μl 0.9% NaCl (Baxter) on the day of infection, and subsequently on days 2, 4 and 6 p.i.
Confocal microscopy analysis
Confocalmicroscopy was performed on 10–20 μm frozen spleen sections as previously
described [71,72]. Briefly, tissues from infected and un-infectedmouse spleens were snap frozen
in embedding optimal cutting temperature (OCT)medium (Sakura) and stored at -80°C until
use. Sectionswere fixed in ice-cold acetone for 10 minutes prior to labelling with antibodies
against CD3-Biotin (clone-17A2), B220-PE (clone-RA3-6B2) and ICOS-APC (clone-C398.4A).
Anti-CD3 was detected by streptavidin conjugated to Alexa Fluor 594. All antibodies were
obtained from Biolegend (San Diego, CA). DAPI was used to aid visualization of white pulp
areas. Samples were imaged on a Zeiss 780-NLO laser-scanning confocal microscope (Carl
ZeissMicroimaging) and data analysed using Imaris image analysis software, version 8.1.2 (Bit-
plane). Cells were identified using the spots function in Imaris, with thresholds<10μm and
intensities<150. T-B borders were defined by the region betweenCD3+ cells closest to the B
IFNAR1 Obstructs Humoral Immunity to Malaria
PLOS Pathogens | DOI:10.1371/journal.ppat.1005999 November 3, 2016 20 / 26
cell follicle and B220+ cells furthest into the T-cell zone. All objects were manually inspected for
accuracy before data were plotted and analyzed in GraphPad Prism (version 6)
Statistical analysis
Comparisons between two groups were performed using non-parametricMann-Whitney
(unpaired datasets) or Wilcoxon (paired datasets) tests. Where depicted, one-way or two-way
ANOVA and Tukey’s post-test were employed for multiple comparisons among three or
more groups. p< 0.05 was considered significant (p<0.05 = ; p<0.01 = ; p<0.001 = ;
P<0.0001 = ). Survival graphs were assessed using Log-rank (Mantel-Cox) tests. Graphs
depict mean values ± SEM, except where individual mouse data points are depicted, in which
case median values are shown. All statistical analyses were performed using GraphPad Prism
v6 or v7 software.
Supporting Information
S1 Fig. IFNAR1-signalling suppresses parasite control, plasmablast and GC B-cell
responses during PcAS infection.WT and Ifnar1-/-mice (n = 5–9) were infectedwith PcAS.
(A) A time-course analysis of parasitemia inWT (n = 9/group) and Ifnar1-/-(n = 6/group) mice
Data representative of three independent experiments. Statistics: Mann-Whitney U test,
P<0.01, P<0.05. (B&C) Representative FACS plots (gated on B220+ CD19+ live singlets), pro-
portions and absolute numbers of (B) splenic plasmablasts (B220+CD19+IgDloCD138hi) in naïve
and infectedmice, 6 days p.i., and (C) emerging splenic GC B-cells (B220+CD19+GL7+Fas+) in
naïve and infectedmice, 8 days p.i. Data in B&C representative of three independent experi-
ments. Statistics: Mann-Whitney U test, P<0.01.
(TIF)
S2 Fig. B-cells are required for Tfh responses during PcAS infection.WTmice (n = 5/
group) were pre-treated with anti-CD20 depletingmonoclonal antibody (α-CD20) or control-
IgG before infectionwith PcAS. Representative FACS plots (gated on CD4+ TCRβ+ live sin-
glets), proportions and absolute numbers of splenic CD4+ T cells co-expressing PD1/CXCR5
and Bcl-6/CXCR5, 7 days p.i. Data representative of two independent experiments.Mann-
Whitney U test, P<0.01.
(TIF)
S3 Fig. IFNAR1-signalling limits CD4+ T-cell activation during PcAS and Py17XNL infec-
tion. (A). Representative FACS plots, proportions and numbers of splenic activated CD4+
T-cells (CD4+TCRβ+CD11a+CD49d+ live singlets) inWT and Ifnar1-/- mice (n = 6) 8 days p.i.
with PcAS. (B) Proportions and numbers of splenic activated CD4+ T-cells on day 6 p.i. with
Py17XNL inWTmice (n = 5) treated with α-Ifnar1 or control IgG. (C) Total numbers of sple-
nocytes, B-cells, GC B-cells and plasmablasts in un-infectedWT and Ifnar1-/- mice (n = 5).
Experiments performed once. Statistics: Mann-Whitney U test, P<0.05; P<0.01.
(TIF)
S4 Fig. IFNAR1-signalling proceeds via CD11chi cDC during PcAS infection. 50:50WT
(Ifnar1+/+ CD45.1): Ifnar1-/- (CD45.2) mixed bonemarrow chimeras (n = 6) were infected
with PcAS. Graphs show paired analysis between splenicWT and Ifnar1-/- cDC subsets in indi-
vidual mice for cell-surface expression of CD86, CD40 and ICOS-L, on CD8α+ (TCRβ- B220-
CD11chi MHC-IIhi CD8α+) and CD8α- (TCRβ-B220-CD11chiMHC-IIhiSirpα+CD8-) cDCs, 2
days p.i. (experiment performed once). White symbols denote un-infected control. Statistics:
Wilcoxon test, P<0.05.
(TIF)
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S5 Fig. ICOS-blockade limits serum IFNγ levels in PcAS-infected Ifnar1-/-mice. Ifnar1-/-
mice were infected with PcAS, treated with α-ICOSL (100μg) or control IgG2a and assessed for
IFNγ levels in serumon day 8 p.i. Data is pooled from two independent experiments showing
similar results (n = 6/ experiment). Statistics: Mann-Whitney U test, P<0.01.
(TIF)
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